Turning Point Therapeutics, Inc.
(NASDAQ : TPTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.11%144.830.7%$945.70m
PFEPfizer Inc. 0.04%35.780.9%$901.81m
MRKMerck & Co., Inc. -1.24%82.120.7%$688.07m
ABBVAbbVie, Inc. -0.36%85.601.9%$654.34m
BMYBristol-Myers Squibb Co. 1.00%58.831.0%$620.05m
LLYEli Lilly & Co. -0.46%148.121.1%$558.44m
AZNAstraZeneca Plc 0.81%54.611.2%$247.65m
NVSNovartis AG 0.08%86.370.2%$163.88m
GSKGlaxoSmithKline Plc 0.31%37.500.2%$105.34m
PRNBPrincipia Biopharma, Inc. 0.02%99.970.0%$80.22m
NVONovo Nordisk A/S 0.40%68.540.1%$57.25m
SNYSanofi -0.91%50.330.2%$48.89m
RGENRepligen Corp. 1.65%142.267.1%$48.33m
RPRXRoyalty Pharma Plc 1.04%40.650.2%$47.13m
OPKOPKO Health, Inc. 0.81%3.1011.2%$44.06m

Company Profile

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.